Gynecologic oncologyHumansPoly(ADP-ribose) Polymerase InhibitorsFemaleUnited StatesOvarian Neoplasms
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
Christina Washington, Bhavana Pothuri, Karen Cadoo, Yvette Drew, Rachel Miller-Garcia, Deborah K Armstrong, Roisin E O'Cearbhaill
Published: 202610.1016/j.ygyno.2025.11.020
Abstract
This Society of Gynecologic Oncology review synthesizes updated data from pivotal trials of poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Multiple phase III trials established PARPi as effective maintenance therapy, demonstrating s…
Preview only. Read the full abstract at the source